Apelin-13 TFA 是G 蛋白偶联受体angiotensin II protein J (APJ)的内源性配体，激活G蛋白偶联受体的EC50值为 0.37 nM。Apelin-13 TFA 具有扩张血管和降压作用。Apelin-13 TFA 也可用于 2 型糖尿病及代谢综合征的研究。
| 生物活性 | Apelin-13 TFA is an endogenous ligand for theG-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with anEC50value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome[1][2][3]. |
| IC50& Target | |
体内研究
(In Vivo) | Apelin-13 (200 μg/kg; IP, daily for 4 weeks) improves cardiac function, improves insulin resistance, improves lipid metabolism, significantly decreases TNF-α and leptin on serum, induces the expression of Apelin-12 in serum and markedly elevates GLUT4 and p-AMPKα2 levels[2].
Apelin-13 (10 and 100 μM; ICV, single dosage) increases the spontaneous discharges in the majority of pallidal neurons[4].
| Animal Model: | Goto-Kakizaki (GK) rats (12 weeks old; 240-280 g; fed with a high-fat diet: 66.5% standard chow, 10% lard, 20% sucrose, 2.5% cholesterol and 1% pig bile salt)[2] | | Dosage: | 200 μg/kg | | Administration: | IP, daily for 4 weeks | | Result: | Significantly decreased heart rate; lowered the levels of fasting plasma glucose (FPG), fasting insulin (FINS) and homeostasis model assessment for insulin resistancey (HOMA-IR); decreased serum levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein-cholesterol (LDL-C) and increased high density lipoprotein-cholesterol (HDL-C); decreased NO level, cNOS activity, TNF-α and leptin in serum; induced the expression of Apelin-12. |
| Animal Model: | Adult Wistar rats (SPF, 8-10 weeks, 240-280 g)[4] | | Dosage: | 10 and 100 μM | | Administration: | ICV, single dosage | | Result: | Increased the spontaneous discharges in the majority of pallidal neurons. |
|
| Clinical Trial | |
| 分子量 | |
| 性状 | |
| Formula | |
| Sequence | Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe |
| Sequence Shortening | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Sealed storage, away from moisture | Powder | -80°C | 2 years | | -20°C | 1 year |
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| 溶解性数据 | In Vitro: H2O : 50 mg/mL(30.03 mM;Need ultrasonic) 配制储备液 | 1 mM | 0.6007 mL | 3.0033 mL | 6.0065 mL | | 5 mM | 0.1201 mL | 0.6007 mL | 1.2013 mL | | 10 mM | 0.0601 mL | 0.3003 mL | 0.6007 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： PBS Solubility: 100 mg/mL (60.07 mM); Clear solution; Need ultrasonic
*以上所有助溶剂都可在本网站选购。 |
m.cnreagent.com